Brief: Titan's Probuphine Commercialization Partner, Molteni, Enters Exclusive European Distribution Agreement With Accord
15/09/2020 13:54
Sept 15 (Reuters) - Titan Pharmaceuticals Inc TTNP.O :
* TITAN'S PROBUPHINE® COMMERCIALIZATION PARTNER, MOLTENI,
ENTERS
INTO EXCLUSIVE EUROPEAN DISTRIBUTION AGREEMENT WITH ACCORD
HEALTHCARE
* TITAN PHARMACEUTICALS INC - AGREEMENT WITH ACCORD
HEALTHCARE
EUROPE FOR COMMERCIALIZATION OF SIXMO
* TITAN PHARMACEUTICALS - ENTITLED TO ABOUT $1.1 MILLION IN
FUTURE
MILESTONE PAYMENTS AND ROYALTY PAYMENTS ON NET SALES OF SIXMO,
COMMENCING IN H2 2021
Source text for Eikon: ID:nPn41G4LFa
Further company coverage: TTNP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Titan Pharmaceuticals
See all newsBrief: Titan Pharmaceuticals Announces $1 Million Private Placement Of Convertible Preferred Stock
Brief: Titan Pharmaceuticals- Appoints Brynner Chiam As Acting Principal Executive Officer & Acting Principal Financial Officer Of Co
U.S. STOCKS ON THE MOVE-Newmont, Monopar Therapeutics, TKO Group
Titan Pharma falls as CEO announces resignation
Brief: Titan Pharmaceuticals Enters Into Merger Agreement With Ke Sdn. Bhd.